- Applied DNA Sciences ( NASDAQ: APDN ) said it began analytical validation of a PCR-based monkeypox virus test which is specific for the genetic signature of the monkeypox virus.
- The company said that if the test is validated by its unit Applied DNA Clinical Labs (ADCL), a validation package will be submitted to New York State Department of Health (NYSDOH) for approval.
- The test uses an A17L gene-target specific to monkeypox that enables detection and differentiation of monkeypox virus from other non-variola orthopoxviruses using real-time PCR, APDN said in an Aug. 2 press release.
- APDN +72.95% to $1.22 premarket Aug. 2
For further details see:
Applied DNA stock soars 73% on starting validation of PCR-based monkeypox test